PEAK6
CRSP icon

PEAK6’s CRISPR Therapeutics CRSP Stock Holding History

PEAK6’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1M Buy
295,900
+21,400
+8% +$1.13M 0.03% 460
2025
Q4 		$14.4M Sell
274,500
-96,600
-26% -$5.79M 0.03% 494
2025
Q3 		$24.1M Sell
371,100
-25,000
-6% -$1.44M 0.04% 363
2025
Q2 		$19.3M Sell
396,100
-81,900
-17% -$3.17M 0.04% 394
2025
Q1 		$16.3M Buy
478,000
+464,400
+3,415% +$19.7M 0.04% 404
2024
Q4 		$535K Buy
+13,600
New +$642K ﹤0.01% 2117

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PEAK6's CRSP Position: Q1 2026 in Review

PEAK6 increased its CRISPR Therapeutics (CRSP) stake by 294% in Q1 2026, buying an estimated $4.27M and bringing the position to 108,604 shares worth $5.17M. The position accounts for 0.01% of the portfolio, ranked #884.

PEAK6 first reported a position in CRSP in Q1 2025 and has held it in 3 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • PEAK6 held 108,604 shares of CRISPR Therapeutics worth $5.17M as of Q1 2026.
  • PEAK6 bought 81,030 CRISPR Therapeutics shares in Q1 2026, an estimated $4.27M.
  • CRISPR Therapeutics made up 0.01% of PEAK6's portfolio in Q1 2026, its #884 holding.
  • PEAK6 first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.